Rival accuses Kaleo of cybersquatting in ‘elaborate scheme’

Cybersquatting was most common in the 1990s and early 2000s, with someone snatching a domain and then selling it to the trademark holder for...

The gene therapy era has arrived. So have the challenges.

A landmark regulatory approval has vaulted the cell and gene therapy space to the front of the drug industry's mind. But speedy progress has also...

Medicare proposes raising CAR-T pay, but reimbursement solution years away

CAR-T therapies represent a significant clinical advance for patients with certain types of advanced lymphoma. In clinical testing, Kymriah (tisagenlecleucel) and Yescarta (axicabtagene ciloleucel) induced...

Clinical biomarkers expected to lift R&D productivity: Iqvia

Pharma's recent slump in R&D productivity — the rate of success in relation to the time and effort invested in drug development — has...
The cancer field's largest conference has come and gone, and with it a window into the thousands of clinical trials being run in hopes...
Dive Insight: While California sequencing company Illumina is larger, Oxford's kept itself relevant and recently attracted new cash to fund an expansion. Amgen's seen the sequencing...
Pharma's recent slump in R&D productivity — the rate of success in relation to the time and effort invested in drug development — has...

Follow RXMonthly

News

Lilly to withdraw FDA-approved cancer drug after clinical failure

Lartruvo (olaratumab) was the first new drug approved for soft tissue sarcoma in more than four decades, at the time offering patients with the...

Wave delays key data readout for Huntington’s therapy

Investors reacted negatively to the pushed-back readouts, sending shares of the Singapore-based biotech down nearly 20% between Tuesday's market close and Wednesday's. Wall Street analysts,...

Amgen bone drug application knocked back in Europe

Expectations for Evenity (romosozumab) are modest, and the rejection by the EMA is a "minor setback" for Amgen, according to RBC Capital Markets analyst...

Catalent to buy Paragon for $1.2B as gene therapy...

Biologics have been a business boon to contract manufacturers, Catalent included. Large-molecule drugs are such a focus, in fact, that last year Catalent split its...

Latest articles

CMS chief declines to provide details on Trump healthcare plan

The administration faces increasing pressure to release a concrete healthcare plan as Democratic presidential candidates are eager to keep the national conversation focused...

Roche cancer drug the 3rd approved for pan-tumor use

Aimed at the molecular catalysts of tumor growth, targeted therapies are treatment mainstays across a wide range of cancer types. 

Novo faces shareholder suit over insulin sales disclosures

Novo is best known for its insulin products like Levemir (insulin detemir) and Tresiba (insulin degludec), as well as other diabetes treatments like...

Celgene wins approval for drug key to Bristol buyout

Approval of Inrebic, which was previously known as fedratinib, is the first domino to fall in Bristol-Myers bet on Celgene's product pipeline. 

Subscribe to our newsletter